

*Asim K. Duttaroy and Friedrich Spener (Eds.)*

# **Cellular Proteins and Their Fatty Acids in Health and Disease**



**WILEY-  
VCH**

WILEY-VCH GmbH & Co. KGaA



*Asim K. Duttaroy and Friedrich Spener*  
(Eds.)

**Cellular Proteins and Their Fatty Acids  
in Health and Disease**



*Asim K. Duttaroy and Friedrich Spener (Eds.)*

# **Cellular Proteins and Their Fatty Acids in Health and Disease**



**WILEY-  
VCH**

WILEY-VCH GmbH & Co. KGaA

**Editors:**

**Professor Dr. Asim K. Duttaroy**  
Institute for Nutrition Research  
University of Oslo  
POB 1046 Blindern  
N-0316 Oslo  
Norway

**Professor Dr. Friedrich Spener**  
Institut für Biochemie  
Universität Münster  
Wilhelm-Klemm-Str. 2  
48149 Münster  
Germany

This book was carefully produced. Nevertheless, authors and publisher do not warrant the information contained therein to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

**Library of Congress Card No.: applied for**

**British Library Cataloguing-in-Publication Data**

A catalogue record for this book is available from the British Library.

**Bibliographic information published**

**by Die Deutsche Bibliothek**

Die Deutsche Bibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data is available in the Internet at <<http://dnb.ddb.de>>

© 2003 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

All rights reserved (including those of translation in other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

Printed in the Federal Republic of Germany  
Printed on acid-free paper

**Composition** K+V Fotosatz GmbH, Beerfelden

**Printing** Druckhaus Darmstadt GmbH,  
Darmstadt

**Bookbinding** Buchbinderei Schaumann,  
Darmstadt

**ISBN** 3-527-30437-1

## Preface

Long-chain fatty acids, in addition to providing the cell with energy, are substrates for membrane biogenesis and act as signalling molecules. These fatty acids and their derivatives directly or indirectly regulate cellular processes such as differentiation, development and gene expression as well as the activities of enzymes, membrane receptors and ion channels. Dietary fats have profound effects on gene expression and fatty acid-activated transcription factors (nuclear receptors) may have a fundamental role in regulating energy balance through their sensing of fatty acid flux in metabolically active tissues. Because of the functional roles of these fatty acids and of their structural features and physico-chemical properties, it is important to understand the mechanisms that evolved for uptake and retention of these molecules. The picture emerging is that the cell has multiple binding proteins in the membranes as well as in the aqueous compartments that assure adequate uptake and intracellular movement of long-chain fatty acids and their regulatory action.

This book covers the various aspects of intracellular binding proteins (FABPs, ACBP, SCP-2), such as structure-function, ligand specificity, delivery of ligands by membrane-protein and protein-protein interaction, as well as their expression and roles pertaining to nutrition, health, and disease. Regulation and expression of membrane fatty acid transporters such as FABPpm, FAT, FATP, and ABC transporters are treated in further chapters. In addition, transcription factors PPARs, RXRs, RARs, LXR, and HNF4 which bind fatty acids or their derivatives are also dealt with in depth. They play a central role in regulating the storage and catabolism of dietary fats and essentially all major metabolic paths of lipids appear to be under control of one or more genes regulated by these transcription factors. Their roles in inflammatory disorders, obesity, cancers, and atherosclerosis are also discussed. Since these transcription factors require fatty acids or their derivatives as ligands, FABPs may play important roles in transporting these ligands.

Many leading investigators have contributed their most recent developments to this book. We believe that it will prove to be an invaluable reference text for both those familiar with and those new to the exciting, and ever changing world of cellular proteins whose common denominator is binding of fatty acids.

Finally, we would like to express our thanks to all contributors to this book and to the reviewers for their competent advice. The untiring support and patience of Ines Chyla and the staff at Wiley-VCH is gratefully acknowledged.

Oslo and Münster, February 2003

Asim K. Duttaroy, Oslo  
Friedrich Spener, Münster



## Contents

Preface V

List of Contributors XIX

**Part 1 The Molecular Basis of Protein-Lipid Interaction  
and Functional Consequences 1**

<b>1</b>	<b>Structure-Function of CD36 and Evidence for its Role in Facilitating Membrane Fatty Acid Transport 3</b>
	<i>Chris T. Coburn and Nada A. Abumrad</i>
1.1	Introduction 3
1.2	Primary Structure 4
1.3	Ligand Binding Domains 6
1.4	Membrane Localization and Role in Cell Signaling 6
1.5	CD36 Gene Structure and Regulation 8
1.6	CD36 Deficiency 10
1.7	CD36 and Platelet Function 11
1.8	CD36 and Atherosclerosis 12
1.9	CD36 and Phagocytosis 13
1.10	CD36 and Angiogenesis 14
1.11	CD36 and Malaria 14
1.12	CD36 and Fatty Acid Transport 15
1.12.1	CD36 is Identified as a Mediator of FA Uptake 15
1.12.2	CD36, SHR, and Insulin Resistance 17
1.12.3	CD36 Transgenic and Knockout Mice Models 18
1.12.4	CD36-null Mice – the Fed Phenotype 18
1.12.5	CD36-null Mice – the Fasting Phenotype 22
1.12.6	CD36 and Insulin Responsiveness in the Mouse 23
1.13	Perspectives and Future Directions 24
1.14	References 25

<b>2</b>	<b>Role and Function of FATPs in Fatty Acid Uptake</b>	<b>31</b>
	<i>Jean E. Schaffer</i>	
2.1	Introduction	31
2.2	Identification of Fatty Acid Transporter Proteins	32
2.3	Structure of FATPs	32
2.4	Function of FATPs	34
2.5	Regulation of FATP expression	35
2.6	Significance of FATPs	36
2.7	References	37
<b>3</b>	<b>Function, Expression, and Regulation of Human ABC Transporters</b>	<b>39</b>
	<i>Gerd Schmitz and Thomas Langmann</i>	
3.1	Introduction	39
3.2	Structural Features of ATP Binding Cassette (ABC) Transporters	40
3.3	Overview of Human ABC Gene Subfamilies	41
3.3.1	The ABCA (ABC1) Subfamily	45
3.3.2	The ABCB (MDR/TAP) Subfamily	46
3.3.3	The ABCC (CFTR/MRP) Subfamily	48
3.3.4	The ABCD (ALD) Subfamily	50
3.3.5	The ABCE (OABP) and ABCF (GCN20) Subfamilies	51
3.3.6	The ABCG (White) Subfamily	51
3.4	Diseases and Phenotypes Caused by ABC Transporters	52
3.4.1	Familial HDL-deficiency and ABCA1	52
3.4.2	Retinal Degeneration and ABCA4 (ABCR)	54
3.4.3	Cystic Fibrosis (ABCC7/CFTR)	56
3.4.4	Multidrug Resistance (ABCB1/MDR1, ABCC1/MRP1, ABCG2)	57
3.4.5	Adrenoleukodystrophy (ABCD1/ALD)	58
3.4.6	Sulfonylurea Receptor (ABCC8/SUR)	59
3.5	Function and Regulation of ABC Transporters in Lipid Transport	60
3.5.1	ABCA1 in Macrophage Lipid Transport	61
3.5.2	ABCG1 and Other ABCG members in Sterol Homeostasis	64
3.5.3	ABC Transporters involved in Hepatobiliary Transport	67
3.6	Conclusions and Perspectives	70
3.7	References	70
<b>4</b>	<b>Albumin Receptors – Structure and Function</b>	<b>79</b>
	<i>Nigel J. Brunskill</i>	
4.1	Introduction	79
4.2	The Search for an Albumin Receptor	80
4.2.1	The Endothelium–Albumin Relationship: Early Concepts	80
4.2.2	Identification of Receptors for Native and Modified Albumin in Endothelial Cells	81
4.3	Albumin Receptors in the Kidney	83
4.3.1	Glomerular Handling of Albumin	83
4.3.2	Binding and Uptake of Albumin in the Kidney Proximal Tubule	83

4.4	Megalin and Cubilin as Proximal Tubule Albumin Receptors	84
4.4.1	Megalin	84
4.4.2	Cubilin	86
4.5	Albumin as a Signaling Molecule – Implications for Albumin Receptor Function	87
4.5.1	LDLR Family as Signaling Receptors	88
4.5.2	Megalin as a Signaling Receptor	89
4.6	Summary	90
4.7	References	90
<b>5</b>	<b>Intracellular Lipid Binding Proteins: Evolution, Structure, and Ligand Binding</b>	<b>95</b>
	<i>Christian Lücke, Luis H. Gutiérrez-González, and James A. Hamilton</i>	
5.1	Introduction	95
5.2	The Evolution of Lipid Binding Proteins	95
5.2.1	The Calycin Superfamily	95
5.2.2	The Intracellular Lipid Binding Proteins	96
5.2.3	The Phylogeny of iLBPs	98
5.3	Structural Characteristics of iLBPs	99
5.3.1	The Common Three-dimensional Fold	101
5.3.2	The iLBP Subfamilies	103
5.3.2.1	Subfamily I	103
5.3.2.2	Subfamily II	105
5.3.2.3	Subfamily III	106
5.3.2.4	Subfamily IV	106
5.3.3	Dynamic Properties of iLBPs	107
5.3.4	Mutagenesis Studies	108
5.4	Ligand Binding Assays	109
5.4.1	Microcalorimetry	109
5.4.2	The Lipidex Assay	110
5.4.3	Fluorescence-based Binding Assays	111
5.4.4	The ADIFAB Assay	111
5.4.4.1	Thermodynamic Analysis	112
5.4.4.2	Kinetic Analysis	112
5.4.5	Lipid Binding Preferences	113
5.5	Concluding Remarks	113
5.6	References	114
<b>6</b>	<b>Fatty Acid Binding Proteins and Fatty Acid Transport</b>	<b>119</b>
	<i>Judith Storch and Lindsay McDermott</i>	
6.1	Introduction	119
6.2	Equilibrium Binding of Fatty Acids to FABPs	119
6.3	<i>In vitro</i> Fatty Acid Transfer Properties of FABPs	122
6.4	Transfection Studies of FABP Function	125
6.5	Cellular Fatty Acid Transport via FABP-Protein Interactions	126

6.6	Insights into FABP Function from Null Mice	128
6.7	Perspectives	130
6.8	References	131
<b>7</b>	<b>Structure and Function of SCP-x/SCP-2</b>	<b>135</b>
	<i>Udo Seedorf</i>	
7.1	Introduction	135
7.2	The SCP-2 Gene Family	136
7.3	Structure of SCP-2	139
7.4	Role of SCP-2/SCP-x in Peroxisomal Metabolism	142
7.5	SCP-2/SCP-x Deficiency Affects the Activity of the Peroxisome Proliferator Activated Receptor PPAR $\alpha$	143
7.6	Impact of SCP-2/SCP-x on Cholesterol Metabolism	145
7.7	Acknowledgements	147
7.8	References	147
<b>8</b>	<b>Structure, Function, and Phylogeny of Acyl-CoA Binding Protein</b>	<b>151</b>
	<i>Susanne Mandrup, Nils J. Færgeman, and Jens Knudsen</i>	
8.1	Introduction	151
8.2	The ACBP Family	152
8.3	ACBP Structure and Ligand Binding Specificity	156
8.4	Regulation of ACBP Expression	157
8.4.1	Genomic Organization in Mammals	157
8.4.2	Expression Pattern in Mammals	158
8.4.3	Transcriptional Regulation of the Mammalian ACBP Gene	159
8.5	Expression Profile in Other Eukaryotes	160
8.6	Subcellular Localization	161
8.7	Regulation of Long-chain Acyl CoA Concentrations <i>in vivo</i>	161
8.8	Functions of ACBP	163
8.8.1	Clues obtained from <i>in vitro</i> Studies	163
8.8.2	<i>In vivo</i> Functions in Mammals	165
8.9	Acyl-CoA esters, ACBP, and PPARs	165
8.10	ACBP in African trypanosomes ( <i>T. brucei</i> )	166
8.11	Functions, and Lessons from Yeast	166
8.12	Conclusions and Future Directions	167
8.13	References	168
<b>9</b>	<b>Structure and Function of PPARs and their Molecular Recognition of Fatty Acids</b>	<b>173</b>
	<i>Colin N. A. Palmer</i>	
9.1	PPARs as Nuclear Receptors	173
9.2	DNA Binding	174
9.3	PPARs as Fatty Acid and Drug Binding Receptors	176
9.4	Species Differences in Pharmacology	179
9.5	Co-activator/Co-repressor Interactions	180

9.6	Cross-talk with Inflammatory Signaling	182
9.7	PPARs as Phosphoproteins	183
9.8	References	185
<b>10</b>	<b>Structure and Function of Retinoid Receptors RAR and RXR</b>	<b>191</b>
	<i>Alexander Mata de Urquiza and Thomas Perlmann</i>	
10.1	Retinoids in Development	191
10.2	Retinoid Receptors Transduce Retinoic Acid Signals	193
10.3	Retinoid Receptors Belong to the Nuclear Hormone Receptor Family	194
10.4	Nuclear Receptors Share a Common Structure	194
10.5	The LBD and Ligand-dependent Transactivation	196
10.6	Cross-talk	198
10.7	Co-activators	198
10.8	Co-repressors	199
10.9	Nuclear Receptors from an Evolutionary Perspective	201
10.10	Fatty acids as Endogenous Ligands for RXR	201
10.11	Perspectives	202
10.12	Acknowledgements	203
10.13	References	203
<b>11</b>	<b>Liver X Receptors (LXRs) – Important Regulators of Lipid Homeostasis</b>	<b>209</b>
	<i>Lene K. Juvet and Hilde I. Nebb</i>	
11.1	Introduction	209
11.2	Nuclear Hormone Receptors	209
11.3	The Liver X Receptors, LXR $\alpha$ and LXR $\beta$	210
11.4	The Cholesterol Sensor: LXR	211
11.5	Interplay between Cholesterol and Fatty Acid Metabolism	214
11.5.1	LXR and SREBP-1c Activation: a New Link between Cholesterol and Fatty Acid Regulation	214
11.5.2	Direct Regulation of Target Genes by LXRs in Lipid Metabolism	215
11.5.3	LXRs as Insulin Sensors in Liver	216
11.5.4	Fatty Acid Regulation of LXR	217
11.5.5	LXRs in Adipose Tissue	218
11.6	Summary	219
11.7	Acknowledgements	219
11.8	References	220
<b>12</b>	<b>Acyl-CoA Ligands of HNF-4<math>\alpha</math> and HNF-4<math>\alpha</math>/PPAR<math>\alpha</math> Interplay</b>	<b>225</b>
	<i>Rachel Hertz and Jacob Bar-Tana</i>	
12.1	Transcriptional Activation by HNF-4 $\alpha$	225
12.2	Fatty Acyl-CoA Ligands of HNF-4 $\alpha$	226
12.3	Xenobiotic Ligands of HNF-4 $\alpha$	230
12.4	HNF-4 $\alpha$ and its Ligands in Health and Disease	232

12.4.1	Blood Lipids	232
12.4.2	MODY-1	232
12.4.3	Blood Coagulation	233
12.5	Liver HNF-4 $\alpha$ /PPAR $\alpha$ Interplay in Rodents and Humans	233
12.6	References	236

**Part 2      Role for Proteins in Cellular Homeostasis    239**

**13            Fatty Acid Binding Proteins and their Roles  
in Transport of Long-chain Polyunsaturated Fatty Acids  
across the Feto-placental Unit    241**

*Asim K. Duttaroy*

13.1	Introduction	241
13.2	Fatty Acid Uptake in the Feto-placental Unit	242
13.3	Identification of Membrane-associated Fatty Acid Binding Protein in Human Placenta	243
13.4	Identification and Location of FAT/CD36 and FATP in Human Placental Membranes	246
13.5	Presence of Cytoplasmic Fatty Acid Binding Proteins (FABPs) in Human Placenta	247
13.6	Presence of Nuclear Transcription Factors that Bind Fatty Acids in Human Placenta: Interaction Between Fatty Acid Binding Proteins and PPAR $\gamma$	248
13.7	References	250

**14            Fatty Acid Binding Proteins of the Brain    253**

*Yuji Owada and Hisatake Kondo*

14.1	Introduction	253
14.2	Expression of FABPs in Developing Rat Brain	254
14.2.1	Localization of H-FABP	254
14.2.2	Localization of E-FABP	258
14.2.3	Localization of B-FABP	261
14.3	Significance of FABP Expression in Brain	261
14.4	Perspective	263
14.5	Acknowledgements	263
14.6	References	264

**15            Cross-talk between Intracellular Lipid Binding Proteins  
and Ligand Activated Nuclear Receptors –  
A Signaling Pathway for Fatty Acids    267**

*Christian Wolfrum and Friedrich Spener*

15.1	Introduction	267
15.2	Fatty Acid Activated Nuclear Receptors	268
15.3	Intracellular Lipid Binding Proteins	269

- 15.4 Regulation of Fatty Acid Activated Nuclear Receptor Activity by iLBPs 270
- 15.5 L-FABP 271
- 15.6 A-FABP and E-FABP 274
- 15.7 CRABP-II 276
- 15.8 Other Members of the FABP Family 277
- 15.9 Mechanism of iLBP Import into the Nucleus 278
- 15.10 Conclusions and Perspectives 279
- 15.11 References 281
- 16 Arachidonic Acid Binding Proteins in Human Neutrophils 285**  
*Claus Kerkhoff and Olof Rådmark*
- 16.1 Cellular Functions of Arachidonic Acid 285
- 16.2 The Two Myeloid-related Proteins S100A8 and S100A9 285
- 16.2.1 S100A8 and S100A9 Belong to the S100 Family 285
- 16.2.2 S100A8 and S100A9 Expression is Primarily Restricted to Cells of Myeloid Lineage 287
- 16.2.3 S100A8/A9 Protein Complexes Bind Polyunsaturated Fatty Acids 289
- 16.2.4 Translocation of S100A8 and S100A9 is Accompanied with Arachidonic Acid Transport 291
- 16.3 Putative Intracellular Functions of S100A8/A9 292
- 16.3.1 5-Lipoxygenase (5-LO) and 5-Lipoxygenase Activating Protein (FLAP) 292
- 16.3.2 Cyclooxygenases (COX-1 and COX-2) 294
- 16.3.3 NADPH Oxidase Complex 295
- 16.4 Extracellular Role of the S100A8/A9–Arachidonic Acid Complex 297
- 16.4.1 Transcellular Arachidonic Acid Metabolism 297
- 16.4.2 Cellular Uptake of Long-chain Fatty Acids (LCFAs) 298
- 16.4.3 Participation of S100A8/A9 in the Arachidonic Acid Uptake 299
- 16.5 Conclusion and Future Perspectives 302
- 16.6 References 303
- 17 PPARs, Cell Differentiation, and Glucose Homeostasis 309**  
*Stephen R. Farmer*
- 17.1 Introduction 309
- 17.2 Regulation of PPAR Activity 309
- 17.3 PPARs and Differentiation 311
- 17.3.1 PPAR $\gamma$  311
- 17.3.2 PPAR $\gamma$  and Adipogenesis 312
- 17.3.3 PPAR $\gamma$  and Transcriptional Control of the Pleiotropic Functions of the Adipocyte 315
- 17.4 PPAR $\alpha$  316
- 17.5 PPAR $\delta$  317
- 17.6 PPARs and Control of Glucose Homeostasis: Therapies for Metabolic Syndrome and Type 2 Diabetes 318

17.6.1	PPAR $\gamma$	318
17.6.2	PPAR $\alpha$	321
17.7	Conclusion	322
17.8	Acknowledgements	323
17.9	References	323
<b>18</b>	<b>Role of FABP in Cellular Phospholipid Metabolism</b>	<b>327</b>
	<i>Chris A. Jolly and Eric J. Murphy</i>	
18.1	Fatty Acid Targeting	327
18.2	Phospholipid Metabolism	328
18.2.1	Diacyl Phospholipid Classes	329
18.2.2	Potential Mechanisms for Diacyl Phospholipid Classes	331
18.2.3	Plasmalogen Classes	331
18.2.4	Potential Mechanisms for Plasmalogen Classes	333
18.3	Neutral Lipid Mass	334
18.4	Cellular Phospholipid Composition	334
18.5	Phospholipid Acyl Chain Composition	335
18.5.1	Potential Mechanisms for Fatty Acyl Chain Alterations	336
18.6	Phosphatidic Acid Biosynthesis	337
18.6.1	FABP Increases Phosphatidic Acid Biosynthesis	337
18.6.2	L-FABP Conformers and Phosphatidic Acid Biosynthesis	338
18.6.3	Potential Mechanisms for Stimulation of Phosphatidic Acid Biosynthesis	338
18.6.4	Biological Significance	339
18.7	Conclusions and Perspectives	340
18.8	References	340
<b>19</b>	<b>Membrane-associated Fatty Acid Binding Proteins</b>	
	<b>Regulate Fatty Acid Uptake by Cardiac and Skeletal Muscle</b>	<b>343</b>
	<i>Jan F. C. Glatz, Joost J. F. P. Luiken, Ger J. van der Vusse, and Arend Bonen</i>	
19.1	Introduction	343
19.2	Molecular Mechanism of Muscular Fatty Acid Uptake	344
19.2.1	Passive Diffusional and Protein-mediated Fatty Acid Uptake	344
19.2.2	Membrane-associated Fatty Acid Binding Proteins	346
19.2.3	Putative Mechanism of Cellular Fatty Acid Uptake	347
19.3	Expression of FABPs in Heart and Skeletal Muscles Compared	348
19.4	Regulation of Muscular Fatty Acid Uptake	350
19.4.1	Acute Changes in Muscle Fatty Acid Utilization and Membrane FABPs	350
19.4.2	Signaling Pathway for FAT/CD36 Translocation to and from the Sarcolemma	351
19.4.3	Chronic Changes in Muscle Fatty Acid Utilization and Membrane FABPs	352



19.5	Concerted Action of the Proteins Involved in Muscle Fatty Acid Uptake	353
19.6	Alterations in Fatty Acid Uptake and Membrane FABPs in Disease	354
19.7	Concluding Remarks	355
19.8	Acknowledgements	355
19.9	References	356
<b>20</b>	<b>Intestinal Fat Absorption: Roles of Intracellular Lipid-Binding Proteins and Peroxisome Proliferator-Activated Receptors</b>	<b>359</b>
	<i>Isabelle Niot and Philippe Besnard</i>	
20.1	Introduction	359
20.2	Intestinal LCFA Absorption: A Complex Phenomenon	360
20.2.1	Can LCFA Uptake be a Rate-limiting Step for Intestinal Fat Absorption?	360
20.2.2	Why do Enterocytes Express Different Membrane LBP?	363
20.2.2.1	FABP <sub>pm</sub> /mAspAT: A Protein in Search of a Function	364
20.2.2.2	FATP4: A Plasma Membrane-associated ACS-like Protein?	365
20.2.2.3	Caveolin-1: An LBP and a Caveolae Marker	365
20.2.2.4	FAT/CD36: An Involvement in a Vesicular Trafficking of LCFA?	366
20.2.3	Do the Different Soluble FABPs Exert the Same Function?	368
20.2.4	ACBP: A Universal Long-chain Acyl CoA Transporter	372
20.2.5	An Integrative Working Model	372
20.3	Intestinal LCFA Absorption: A Phenomenon Putatively Adaptable to the Lipid Content of the Diet	374
20.3.1	PPAR and Coordinatd LBP Regulation	374
20.3.2	PPAR $\beta/\delta$ : A Nuclear Receptor Involved in the Regulation of Intestinal Absorptive Area	376
20.4	General Conclusion	377
20.5	References	378
<b>21</b>	<b>Fatty Acid Binding Proteins as Metabolic Regulators</b>	<b>383</b>
	<i>J. M. Stewart</i>	
21.1	Introduction	383
21.2	Established Interactions between Carbohydrate- and Fatty Acid-based Energy Production	384
21.3	The Involvement of FABP in Metabolism: Working Hypothesis	384
21.4	Criteria for Physiological Relevance of Metabolite Modulation of Fatty Acid Binding to FABP	385
21.4.1	Mammalian Liver FABP	386
21.4.2	Mammalian Heart/Muscle FABP	387
21.5	Potential of Formation of Schiff Bases: Non-enzymatic Glycation of FABPs	388

21.6	Theoretical Effects and Implications of Reciprocal Cross-talk: How much Fatty Acid Would be Available to Interact with Hexokinase? 389
21.7	Difference in Binding of Fatty Acids and Modulation between Different Types of FABP 391
21.8	Where Else to Look: Other Enzymes that are Influenced by Fatty Acids 391
21.9	Summary 392
21.10	Acknowledgements 393
21.11	References 394
<b>22</b>	<b>Role of Lipid Binding Proteins in Disease 397</b> <i>Aline Meirhaeghe and Philippe Amouyel</i>
22.1	Polymorphism in <i>FATP1</i> Gene and Triglyceride Metabolism 397
22.1.1	Fatty Acid Metabolism 397
22.1.2	<i>FATP1</i> Polymorphisms 398
22.1.3	<i>FABP2</i> Polymorphisms 399
22.2	References 400
<b>23</b>	<b>PPARs in Atherosclerosis 401</b> <i>Jorge Plutzky</i>
23.1	Atherosclerosis 401
23.1.1	Introduction 401
23.1.2	Atherosclerosis as a Clinical Syndrome 402
23.1.3	Cellular Constituents of Atherosclerosis 403
23.1.4	Atherosclerosis as an Inflammatory Disorder 404
23.1.5	Atherosclerosis as a Metabolic Disorder 404
23.2	PPAR in the Vasculature 405
23.2.1	PPARs in Vascular Biology and Atherosclerosis 405
23.2.2	Examining Evidence for PPAR in Vascular Responses 406
23.3	PPAR $\gamma$ in Vascular Biology and Atherosclerosis 407
23.3.1	<i>In vitro</i> Evidence 407
23.3.2	<i>In vivo</i> Evidence 408
23.4	PPAR $\alpha$ in Vascular Biology and Atherosclerosis 409
23.4.1	<i>In vitro</i> Evidence 409
23.4.2	<i>In vivo</i> Evidence 411
23.5	PPAR $\delta$ in Vascular Biology and Atherosclerosis 413
23.6	Conclusion 413
23.7	References 414

<b>24</b>	<b>PPARs: Nuclear Hormone Receptors Involved in the Control of Inflammation</b>	<b>419</b>
	<i>Liliane Michalik, Nguan Soon Tan, Walter Wahli, and Béatrice Desvergne</i>	
24.1	Introduction	419
24.2	PPAR Expression Profiles and Modulation by Cytokines	420
24.3	Fatty Acids and their Metabolites are PPAR Ligands	421
24.4	PPARs and the Control of the Inflammatory Response	423
24.4.1	Anti-inflammatory Properties of PPAR $\alpha$	423
24.4.2	PPAR $\beta$ and the Keratinocyte Response to Inflammation	425
24.4.3	PPAR $\gamma$ is Involved in the Control of Inflammation	427
24.5	Are PPARs Good Targets for the Treatment of Inflammatory Disorders?	428
24.5.1	PPARs in Skin Inflammatory Disorders	428
24.5.2	PPARs and the Progression of Atherosclerosis	428
24.5.3	PPAR $\gamma$ Regulates Intestinal Inflammation	431
24.6	Conclusion	431
24.7	Acknowledgements	432
24.8	References	433
<b>25</b>	<b>PPARs and Cancer</b>	<b>437</b>
	<i>J. H. Gill and Ruth A. Roberts</i>	
25.1	Introduction	437
25.2	The PPAR Family	437
25.3	PPAR $\alpha$	438
25.3.1	Expression and Activation	438
25.3.2	PPAR $\alpha$ and Cancer	439
25.3.3	Species Differences	439
25.3.4	PPAR $\alpha$ as a Therapeutic Target?	440
25.4	PPAR $\gamma$	441
25.4.1	Expression and Activation	441
25.4.2	PPAR $\gamma$ and Cancer	442
25.4.3	PPAR $\gamma$ as a Therapeutic Target?	442
25.5	PPAR $\beta$	443
25.5.1	Expression and Activation	443
25.5.2	PPAR $\beta$ and Cancer	443
25.5.3	PPAR $\beta$ as a Therapeutic Target?	444
25.6	Future Directions	444
25.7	References	445

<b>Subject Index</b>	<b>449</b>
----------------------	------------



## List of Contributors

PHILIPPE AMOUEYEL  
INSERM U508  
Institut Pasteur de Lille  
1 rue du professeur Calmette  
BP 245  
59019 Lille Cedex  
France

AREND BONEN  
Department of Kinesiology  
University of Waterloo  
Waterloo, ON N2L 3G1  
Canada

NIGEL J. BRUNSKILL  
Department of Cell Physiology  
and Pharmacology  
Department of Nephrology  
University of Leicester  
Medical Sciences Building  
University Road  
Leicester, LE1 9HN  
UK

CHRIS T. COBURN  
and NADA A. ABUMRAD  
Department of Physiology  
and Biophysics  
Stony Brook University  
Stony Brook, NY 11794-8661  
USA

A. K. DUTTARAY  
Institute for Nutrition Research  
University of Oslo  
P.O. Box 1046 Blindern  
0316 Oslo  
Norway

STEVE FARMER  
Boston University of School  
of Medicine  
Department of Biochemistry  
715 Albany St.  
Boston, MA 02118  
USA

JASON H. GILL  
Molecular Pathology  
Cancer Research Unit  
University of Bradford  
All Saints Road  
Bradford BD7 1DP  
UK

JAN F. C. GLATZ, JOOST J. F. P. LUIKEN  
and GER J. VAN DER VUSSE  
Department of Physiology, CARIM  
Maastricht University  
P.O. Box 616  
6200 MD Maastricht  
The Netherlands

LUIS H. GUTIÉRREZ-GONZÁLEZ  
Institut für Organische Chemie  
und Biochemie II  
Technische Universität München  
Lichtenbergstr. 4  
85747 Garching  
Germany

RACHEL HERTZ and JACOB BAR-TANA  
Department of Human Nutrition  
and Metabolism  
Hebrew University Medical School  
91120 Jerusalem  
Israel

CHRIS A. JOLLY  
Division of Nutritional Sciences  
University of Texas at Austin  
Gearing Hall 117  
Austin, TX 78712  
USA

LENE K. JUVET and HILDE I. NEBB  
Institute for Nutrition Research  
University of Oslo  
P.O. Box 1046 Blindern  
0316 Oslo  
Norway

CLAUS KERKHOFF  
Institut für Experimentelle  
Dermatologie  
Universität Münster  
Von Esmarch Straße 56  
48149 Münster  
Germany

CHRISTIAN LÜCKE  
and JAMES A. HAMILTON  
Department of Physiology  
and Biophysics  
Boston University School of Medicine  
Boston, MA 02118  
USA

SUSANNE MANDRUP, NILS J. FÆRGEMAN  
and JENS KNUDSEN  
Department of Biochemistry  
and Molecular Biology  
University of Southern Denmark  
Campusvej 55  
5230 Odense M  
Denmark

ALEXANDER MATA DE URQUIZA  
and THOMAS PERLMANN  
Ludwig Institute for Cancer Research  
Karolinska Institute  
P.O. Box 240  
17177 Stockholm  
Sweden

LINDSAY McDERMOTT  
Department of Chemistry  
University of Glasgow  
Glasgow G12 8QQ  
UK

ALINE MEIRHAEGHE  
Clinical Chemistry  
Addenbrooke's Hospital – Level 4  
Hills Road  
Cambridge CB2 2QR  
UK

LILIANE MICHALIK, NGUAN SOON TAN,  
WALTER WAHLI  
and BÉATRICE DESVERGNE  
Institut de Biologie Animale  
Bâtiment de Biologie  
Université de Lausanne  
1015 Lausanne  
Switzerland

ERIC J. MURPHY  
Department of Pharmacology,  
Physiology and Therapeutics  
University of North Dakota  
501 N. Columbia Rd., Room 3700  
Grand Forks, ND 58203  
USA

OLOF RADMARK  
Department of Medical Biochemistry  
and Biophysics  
Division of Physiological Chemistry II  
Karolinska Institutet  
17177 Stockholm  
Sweden

ISABELLE NIOT and PHILIPPE BRESNARD  
Laboratoire de Physiologie  
de la Nutrition (ENSBANA)  
Université de Bourgogne  
1, Esplanade Erasme  
21000 Dijon  
France

RUTH A. ROBERTS  
Aventis Pharma SA  
Centre de Recherche de Paris  
94400 Vitry sur Seine  
France

YUJI OWADA and HISATAKE KONDO  
Division of Histology  
Department of Cell Biology  
Graduate School of Medical Science  
Tokohu University  
2-1 Seiryō-cho, Aoba-ku  
Sendai 981-8575  
Japan

JEAN E. SCHAFFER  
Departments of Internal Medicine  
Molecular Biology and Pharmacology  
Washington University School  
of Medicine  
660 South Euclid Ave  
Box 8086  
St. Louis, MO 63110-1010  
USA

COLIN N.A. PALMER  
Biomedical Research Centre  
Nienewells Hospitals and Medical  
School  
University of Dundee  
Dundee DD1 9SY  
UK

GERD SCHMITZ  
and THOMAS LANGMANN  
Institut für Klinische Chemie  
und Laboratoriumsmedizin  
Universität Regensburg  
Franz-Josef-Strauß-Allee 1  
93042 Regensburg  
Germany

JORGE PLUTZKY  
Cardiovascular Division  
Department of Medicine  
Brigham and Women's Hospital  
Harvard Medical School  
221 Longwood Ave., LMRC 307  
Boston, MA 02115  
USA

UDO SEEDORF  
Institut für Arterioskleroseforschung  
Domagkstr. 3  
48149 Münster  
Germany

FRIEDRICH SPENER  
Institut für Biochemie  
Universität Münster  
Wilhelm-Klemm-Str. 2  
48149 Münster  
Germany

JACK M. STEWART  
Biochemistry Program  
Department of Biology  
Mount Allison University  
Sackville, NB E4L 1G7  
Canada

CHRISTIAN WOLFRUM  
Rockefeller University  
1230 Yorck Ave.  
New York, NY 10021  
USA

JUDITH STORCH  
Department of Nutritional Sciences  
Rutgers University  
New Brunswick, NJ 08901  
USA



**Part 1**

**The Molecular Basis of Protein-Lipid Interaction  
and Functional Consequences**



# 1

## Structure-Function of CD36 and Evidence for its Role in Facilitating Membrane Fatty Acid Transport

CHRIS T. COBURN and NADA A. ABUMRAD

### 1.1

#### Introduction

CD36 (also known as GPIV, GPIIb, PAS IV, and FAT) is an integral membrane glycoprotein with a wide cellular distribution. It has been identified on the surface of megakaryocytes, erythroid precursors, platelets, monocytes, dendritic cells, adipocytes, myocytes, retinal and mammary epithelial cells, and endothelial cells of the microvasculature and small intestine. Depending upon the cellular context, CD36 may perform its primary role as a mediator of fatty acid (FA) uptake, a cell adhesion molecule, or a class B scavenger receptor. This remarkable versatility may reflect both the diverse tissue distribution of CD36 and its ability to interact with a wide variety of ligands.

CD36 binds long-chain FA with high affinity and is a major facilitator of FA uptake in muscle and adipose tissues. As a receptor for the extracellular matrix proteins thrombospondin 1 (TSP-1) and collagens type I and IV, CD36 acts as an adhesion molecule modulating platelet aggregation and the cell–cell interactions important for recruitment and trafficking of monocytes to damaged tissues. In a pathological context, CD36 is the receptor in the microvasculature for the *Plasmodium falciparum* protein expressed on the surface of malaria-infected erythrocytes and as a result contributes to the virulence of this form of malaria. In macrophages and dendritic cells, CD36 is a scavenger receptor important to recognition and phagocytosis of apoptotic cells. On macrophages it is also the major receptor mediating binding and internalization of oxidized low-density lipoproteins (oxLDL), a role reflecting its ability to bind anionic phospholipids as well as lipids or proteins modified by lipid peroxidation.


Because of the varied roles of CD36, a great deal has been discovered about this protein. With functions impacting on lipid metabolism, atherogenesis and thrombosis, inflammation, platelet function, the pathogenesis of malaria and even angiogenesis, further study of the physiology and molecular interactions of CD36 will no doubt continue to progress at a rapid pace. This chapter presents an overview of current knowledge with particular emphasis given to the role of CD36 in lipid metabolism and metabolic homeostasis.

## 1.2

**Primary Structure**

CD36 is the founder member of a gene family of structurally related glycoproteins expressed at the cell surface and within lysosomes. Known members include, in addition to CD36, the high-density lipoprotein receptor SR-B1 (also CLA-1), *Drosophila* plasma membrane proteins emp and croquemort, the ubiquitously expressed lysosomal integral membrane protein LIMPII, and the recently identified amoeboid endolysosomal proteins LmpA, LmpB, and LmpC. All are believed to share a “hairpin” topology defined by two transmembrane domains with both termini in the cytoplasm (Fig. 1.1). In this configuration, the intervening amino acids localize either to the cell surface (CD36) or to the lumen of lysosomal vesicles (LIMPII). This arrangement is exceedingly rare among membrane proteins but has been experimentally confirmed for both CD36 and SR-B1 [1, 2].

Numerous studies have contributed to the development of a detailed model for the primary structure of CD36 (Fig. 1.1). The human cDNA predicts a sequence of 472 amino acids with an N-terminal signal peptide directing transcription to the endoplasmic reticulum (residues 1–30). Limited N-terminal sequencing of purified CD36 shows that the signal peptide is uncleaved but the initiating methio-



**Fig. 1.1** Cartoon of CD36 in the membrane, highlighting the major structural features. N-linked glycosylations are shown as triangles. Disulfide bonds are shown in green.

nine is removed. Residues 2–7 are in the cytoplasm while 8–30 form the N-terminal membrane-spanning domain. The second transmembrane domain (440–463) is near the C-terminus. An uninterrupted hydrophobic segment (186–204) is centrally located but not long enough to span the bilayer. This segment, which may form a hydrophobic pocket or may be associated with the outer leaflet, is not conserved in other known members of the CD36/LIMP-II family.

The cytoplasmic domain of CD36 consists of only 15 amino acids (6 at the N-terminus and 9 at the C-terminus). It contains four cysteines (N residues 3 and 7 and C residues 464 and 466), which were shown to undergo palmitoylation, confirming the membrane topology [1]. From examples of other acylated proteins, it can be speculated that palmitoylation of the cytoplasmic domain may play an important role in modulating interactions with other proteins and/or membrane localization. Since palmitoylation is reversible, a variable palmitoylation state may also serve to acutely regulate CD36 function. In this respect, in isolated rat adipocytes, insulin or energy depletion with 2,4-dinitrophenol was shown to rapidly increase CD36 palmitoylation by about 3- and 12-fold, respectively [3].

The extracellular domain of CD36 contains 10 potential glycosylation sites and glycosylation increases the apparent protein mass from 53 kDa (non-glycosylated) to between 78 and 88 kDa, depending on the tissue source. Extensive glycosylation is a characteristic of the CD36/LIMP-II family of proteins perhaps affording protection in the protease-rich environments of lysosomes or at sites of inflammation and tissue injury. Indeed, CD36 was initially identified in platelets based on its resistance to protease digestion [4] and deglycosylation with endoglycosidase F yields a protein that is susceptible to a range of proteases [5]. A cursory examination of the primary structure of CD36 shows a natural division between the N- and C-terminal halves of the extracellular domain. The N-terminal half contains 7 of the 10 potential N-linked glycosylation sites as well as the internal hydrophobic domain, while the C-terminal half is proline-rich and contains all of the extracellular cysteines and subsequent interchain disulphide bonds. Whether this may translate into separate functional domains remains to be determined.

In megakaryocytes and in CD36-transfected COS cells, Thr92, which fits within a protein kinase C consensus site, is constitutively phosphorylated during maturation of the protein in the Golgi apparatus [6]. The phosphorylation state of this residue appears to modulate the selectivity of CD36 on platelets for TSP-1 or collagen binding. A cAMP-dependent ectoprotein kinase A on the surface of platelets has also been shown to phosphorylate CD36 [7]. The phosphorylated residue was not determined but most likely occurs within a protein kinase A (PKA) consensus site around Ser237, though PKA phosphorylation of Thr92 cannot be ruled out. No functional change in CD36 activity has yet been attributed to this phosphorylation event.

### 1.3

#### Ligand Binding Domains

Monoclonal antibodies have been used to identify CD36 domains involved in ligand binding. Amino acids 155–183 define an immunodominant region shown to bind a number of anti-CD36 monoclonal antibodies, including the widely used OKM5 [8]. These antibodies block interactions of CD36 with TSP-1, OxLDL, malaria-infected red blood cells, apoptotic neutrophils, and phosphatidylserine [9–13]. Since antibody binding to CD36 might sterically hinder ligand interaction, synthetic and recombinant peptides have been used to more closely define the binding domains. These studies have shown that OxLDL and TSP-1 bind to sequences outside of the immunodominant domain. OxLDL binds with high affinity to CD36 amino acids 28–93 [14]. TSP-1 binds in a two-step process interacting first with CD36 residues 139–155. This induces a conformational change in TSP-1 unmasking a high-affinity site for amino acids 93–120 of CD36 [15]. Malaria-infected erythrocytes also bind within this region (residues 97–110) [6].

A possible site for long-chain FA binding in the extracellular domain of CD36 has been identified with an alignment comparing CD36 sequence with that of a representative member of the lipocalin family of cytosolic FA binding proteins [16]. Members of this family may exhibit as little as 20% sequence identity but share a common and distinct structural motif. The region comprising amino acids 127–279 of CD36 exhibits homology to human muscle FA binding protein (M-FABP) throughout 73% of its sequence, although identity is only 14.5%. Secondary structure predictions indicate this sequence may consist of a single  $\alpha$ -helical region interposed between regions of sheets similar to the known structure of M-FABP and other lipocalin family members. It is also of interest that of the amino acids conserved throughout the lipocalin family, Arg126 and Tyr128 of M-FABP, which interact with the FA carboxyl group and are necessary for FA binding, are conserved in this alignment (Arg272 and Tyr275 of CD36). It may be noteworthy that this region includes the hydrophobic domain of CD36 (186–204), thought to be membrane associated or to form a hydrophobic pocket.

### 1.4

#### Membrane Localization and Role in Cell Signaling

CD36 in many cells is associated with membrane microdomains rich in cholesterol and sphingolipid and known as rafts or caveolae. The long, largely saturated acyl chains of the sphingolipids favor tight packing with cholesterol and promote formation of small freely floating domains (hence rafts) within the membrane (reviewed in Ref. [17]). These detergent-resistant membranes (DRM), which can be biochemically isolated from the rest of the membrane by virtue of their insolubility in Triton X-100 at 4°C, typically account for about 5% of the plasma membrane of mammalian cells. Although sphingolipid-rich rafts are mostly confined to the outer leaflet they are coupled to similar domains incorporating mono-un-